Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine

被引:22
作者
Gardin, JM
Weissman, NJ
Leung, C
Panza, JA
Fernicola, D
Davis, KD
Constantine, GD
Reid, CL
机构
[1] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA
[2] Washington Hosp Ctr, Inst Cardiovasc Res, Washington, DC 20010 USA
[3] NHLBI, Cardiol Branch, Bethesda, MD 20892 USA
[4] Wyeth Ayerst Res, Philadelphia, PA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2001年 / 286卷 / 16期
关键词
D O I
10.1001/jama.286.16.2011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Use of anorexigen therapy is associated with valvular abnormalities, although there is limited information on long-term changes in valvular regurgitation following discontinuation of these agents. Objective To evaluate changes in valvular regurgitation, valve morphology, and clinical parameters 1 year after an initial echocardiogram in patients previously treated with dexfenfluramine or phentermine/fenfluramine and in untreated controls. Design and Setting A reader-blinded, multicenter, echocardiographic and clinical 1-year follow-up study at 25 outpatient clinical sites. Patients A total of 1142 obese patients (1466 participated in the initial study) who had follow-up echocardiogram; all but 4 had a follow-up medical history and physical examination. Follow-up time from discontinuation of drug to follow-up echocardiogram for 371 dexfenfluramine patients was 17.5 months (range, 13-26 months) and for 340 phentermine/fenfluramine patients was 18.7 months (range, 13-26 months) after discontinuation of drug therapy. Main Outcome Measure Change in grade of valvular regurgitation and valve morphology and mobility. Results Echocardiographic changes in aortic regurgitation were observed in 8 controls (7 [1.7%] had decreases; 1 [0.2%]had an increase); 29 dexfenfluramine patients (23 [6.4%] had decreases; 6 [1.7%] had increases; P<.001 vs controls); and 15 phentermine/fenfluramine patients (4.5% all decreases; P=.03 vs controls). No statistically significant differences were observed when treated patients were compared with controls for changes in medical history, physical findings, mitral regurgitation, aortic or mitral leaflet mobility or thickness, pulmonary artery systolic pressure, ejection fraction, valve surgery, or cardiovascular events. Conclusion Progression of valvular abnormalities is unlikely in patients 1 year after an initial echocardiogram and 13 to 26 months after discontinuation of dexfenfluramine and phentermine/fenfluramine.
引用
收藏
页码:2011 / 2014
页数:4
相关论文
共 12 条
[1]   Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine [J].
Gardin, JM ;
Schumacher, D ;
Constantine, G ;
Davis, KD ;
Leung, C ;
Reid, CL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13) :1703-1709
[2]   COLOR DOPPLER ASSESSMENT OF MITRAL REGURGITATION WITH ORTHOGONAL PLANES [J].
HELMCKE, F ;
NANDA, NC ;
HSIUNG, MC ;
SOTO, B ;
ADEY, CK ;
GOYAL, RG ;
GATEWOOD, RP .
CIRCULATION, 1987, 75 (01) :175-183
[3]   Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine [J].
Hensrud, DD ;
Connolly, HM ;
Grogan, M ;
Miller, FA ;
Bailey, KR ;
Jensen, MD .
MAYO CLINIC PROCEEDINGS, 1999, 74 (12) :1191-1197
[4]   Fenfluramine and phentermine and cardiovascular findings - Effect of treatment duration on prevalence of valve abnormalities [J].
Jollis, JG ;
Landolfo, CK ;
Kisslo, J ;
Constantine, GD ;
Davis, KD ;
Ryan, T .
CIRCULATION, 2000, 101 (17) :2071-2077
[5]   Prevalence and correlates of aortic regurgitation in American Indians: The strong heart study [J].
Lebowitz, NE ;
Bella, JN ;
Roman, MJ ;
Liu, JE ;
Fishman, DP ;
Paranicas, M ;
Lee, ET ;
Fabsitz, RR ;
Welty, TK ;
Howard, BV ;
Devereux, RB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (02) :461-+
[6]  
MANCINI MC, 1999, INT J OBES RELAT MET, V23, pS178
[7]   The progression of fenfluramine-associated valvular heart disease assessed by echocardiography [J].
Mast, ST ;
Jollis, JG ;
Ryan, T ;
Anstrom, KJ ;
Crary, JL .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (04) :261-266
[8]   EVALUATION OF AORTIC-INSUFFICIENCY BY DOPPLER COLOR FLOW MAPPING [J].
PERRY, GJ ;
HELMCKE, F ;
NANDA, NC ;
BYARD, C ;
SOTO, B .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 9 (04) :952-959
[9]   Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine [J].
Ryan, DH ;
Bray, GA ;
Helmcke, F ;
Sander, G ;
Volaufova, J ;
Greenway, F ;
Subramaniam, P ;
Glancy, DL .
OBESITY RESEARCH, 1999, 7 (04) :313-322
[10]   Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine [J].
Shively, BK ;
Roldan, CA ;
Gill, EA ;
Najarian, T ;
Loar, SB .
CIRCULATION, 1999, 100 (21) :2161-2167